Biotechs grabbed $1.83B in VC cash in Q3. Still fast but a lit­tle less fu­ri­ous

Biotech VCs in the US con­tin­ued to steam along in the third quar­ter, rack­ing up $1.8 bil­lion in new in­vest­ments. That marks a slight drop from the same pe­ri­od a year ago, but 2016 is still out­strip­ping every­thing else on the record books aside from the siz­zling stretch through 2015.

The to­tal tots up as $5.5 bil­lion for the first nine months of the year, as VCs con­tin­ue to splurge on their port­fo­lio of new and ex­ist­ing drug de­vel­op­ers. By this point last year, the to­tal for the year topped $6 bil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER